Editorial Standards
How we research, review, and update this guide
Every Accountably guide is researched against primary IRS sources, reviewed by a U.S. CPA, and refreshed as guidance evolves. Read our Editorial Guidelines to see how we source, fact-check, and update our content.
Plenty of people assume Form 8947 is optional paperwork that the IRS data will sort out on its own. It is not. For covered entities with more than $5,000,000 in branded prescription drug sales to specified government programs, filing is mandatory, and the form is what feeds the data the IRS uses to set the annual branded prescription drug fee under ACA section 9008.
Miss it and the fee does not pause; it just gets calculated without your orphan drug exclusions and rebate offsets, so the number comes back higher than it should. The deadline is November 1, the next business day on a weekend, which made it November 3, 2025 for that cycle. The IRS issues a preliminary calculation and then a final fee letter no later than August 31, with error reports generally due by May 15 of the fee year.
Key Takeaways
- Form 8947 is used by covered entities that manufacture or import branded prescription drugs to give the IRS key data, for example National Drug Codes, Medicaid supplemental rebates, and Section 45C orphan drug information, that can affect the annual Branded Prescription Drug Fee. Filing is mandatory for covered entities above the $5,000,000 threshold, and it directly informs the IRS data set, and skipping it typically raises your assessed fee because the IRS cannot apply your Section 45C orphan drug exclusions or Medicaid state supplemental rebate offsets without it.
- Timing matters. For covered entities above the threshold, Form 8947 is due by November 1 of the year before the fee year, or the next business day when November 1 falls on a weekend or federal holiday. Payment of the final fee is due by September 30 of the fee year.
- The IRS issues a preliminary calculation, then a final fee letter no later than August 31. You can dispute via the error report process if agency data is off, but error reports are generally due by May 15 of the fee year, and issues not raised by then usually cannot be corrected before the September 30 payment date.
- If you later need a refund related to the fee, the IRS instructs you to use Form 843 and include the Form 8947 that supported the IRS calculation.
- Do not confuse Form 8947 with investor reporting like Form 1099‑B or individual reporting on Form 8949. Form 8947 is about the branded prescription drug fee under ACA section 9008, not broker corrections.
What Form 8947 Is, and Who It Is For
Form 8947, Report of Branded Prescription Drug Information, is how a covered entity reports drug and rebate data that the IRS uses when it calculates the annual Branded Prescription Drug Fee under section 9008 of the Affordable Care Act. The form asks for National Drug Codes, Medicaid state supplemental rebates, Section 45C orphan drug information, and details about your designated entity and controlled group, if applicable. Filing is mandatory for covered entities over the threshold, and it is the official way to make sure the IRS sees your corrections and exclusions before it runs the numbers.
Who is a “covered entity”? It is generally a manufacturer or importer of branded prescription drugs with sales to specified federal programs, but only an entity with gross receipts from branded prescription drug sales to a specified government program exceeding $5,000,000 in the data year is required to file. If you fall into that category, you do not file a tax return for this fee, you respond to the IRS timeline, and you pay electronically by the deadline.
How Form 8947 Fits Into the Branded Prescription Drug Fee
Think of the process in four beats.
- Sales year and two‑year lag The fee for a given calendar year is based on sales to government programs from the second preceding year. For example, the 2025 fee uses 2023 sales data. This two‑year lag gives agencies and the IRS time to assemble consistent, validated data.
- Your chance to supply corrections Each covered entity may submit Form 8947 with the NDCs it labels, Medicaid supplemental rebate amounts, Section 45C orphan drug information, and controlled group details. This helps the IRS properly exclude qualifying orphan drug sales and reduce the sales base by applicable rebates before it issues the preliminary calculation.
- IRS preliminary and final calculation The IRS compiles data from CMS, VA, and DOD by NDC, applies the rules in the regulations, and sends a preliminary fee calculation. You can dispute data through the error report process. The final fee letter arrives no later than August 31.
- Payment and non‑deductibility You must pay the final fee by September 30, and the fee is non‑deductible under section 275. Payment is by electronic funds transfer. For controlled groups, payment uses the designated entity’s EIN, and all members are jointly and severally liable.
A quick word on common confusion
A lot of tax teams mix up 8947 and 8949 because the numbers are similar. Form 8949 is for reporting capital asset sales on individual or business returns and reconciles with Forms 1099‑B or 1099‑S. Form 8947 is unrelated to securities, it is strictly tied to the branded prescription drug fee. If you are searching for “basis fixes” or “wash sales,” you are looking for forms 1099‑B and 8949, not 8947.
Accountably note, if your firm supports manufacturers or importers and you need disciplined help assembling NDC lists, rebate support, and orphan drug evidence for Form 8947, an embedded team that works inside your templates and checklists keeps this process clean and on time. Use it sparingly, use it when it saves your reviewers hours, then focus your in‑house team on disputes and strategy.
Timeline, Deadlines, and What Happens When
Here is the life cycle most teams follow each fee year, with the dates you should plan around.
- November 1 filing deadline Covered entities above the threshold must file Form 8947 by November 1 of the year before the fee year, or the next business day if November 1 lands on a weekend or federal holiday. Example, for the 2025 fee year, the due date to submit information for the 2023 sales year was Friday, November 1, 2024. For the 2026 fee year, the due date fell on the next business day because November 1, 2025 was a weekend date.
- Preliminary calculation and dispute window The IRS compiles brand‑by‑NDC data from CMS, VA, and DOD, applies your 8947 inputs, then issues a preliminary calculation to each covered entity. If something looks off, you use the dispute process and submit an error report to the Ogden address by May 15 of the fee year; errors not raised by then generally cannot be corrected before the September 30 payment date.
- Final fee letter The IRS sends the final fee calculation letter no later than August 31 of the fee year. This reflects any changes from the dispute process.
- Payment The final fee is due by September 30, paid by electronic funds transfer. Controlled groups must pay under the designated entity’s EIN.
Quick reference dates
| Milestone | What to do | Typical timing |
| Form 8947 submission window | Required for covered entities above the $5,000,000 threshold; submit NDCs, Medicaid supplemental rebates, Section 45C orphan drug info, controlled group and designated entity details | By November 1 of the year before the fee year, or the next business day |
| Preliminary calculation | Review and, if needed, dispute via error report | Issued during the fee year, before final letter |
| Final fee letter | Confirm final amount | No later than August 31 of the fee year |
| Fee payment | Pay by EFT using designated entity EIN if a controlled group | No later than September 30 of the fee year |
These dates and steps come straight from IRS program pages and the Internal Revenue Manual for the Branded Prescription Drug Fee.
What You Must Include on Form 8947
Form 8947 is a dynamic Adobe LiveCycle PDF that expands with the number of NDCs you report, so its page count varies, and the data behind it is detailed. At a minimum, be ready to provide the following.
- National Drug Codes for each branded prescription drug under your labeler code for the sales year.
- Medicaid state supplemental rebate information for the sales year. Tie amounts to your accounting method.
- Section 45C orphan drug information, including the latest year the 45C credit was allowed for that drug.
- Designated entity and controlled group members as of year end, if applicable.
- Contact details that support quick follow up during the dispute window. The IRS also offers a secure messaging channel for fee‑related communications, although fee letters are not sent through that system.
Practical tip, list your NDCs exactly as labeled, keep your orphan drug substantiation handy, and reconcile Medicaid supplemental rebates to your ledger and state confirmations. These items directly affect the sales base the IRS uses.
Where to send Form 8947 and error reports
The Internal Revenue Manual provides the Ogden, Utah address used for Form 8947 submissions and error reports. Use the current address and mail stop as published by the IRS. Keep proof of mailing and a digital package of what you sent.
How the IRS Calculates the Fee, in Plain English
- Start with the “applicable amount,” the total industry fee set by statute.
- Determine each covered entity’s “sales taken into account,” which uses a percentage table that increases with larger sales bands and excludes qualifying orphan drug sales.
- Allocate the fee based on each entity’s share of sales taken into account.
- Apply the annual adjustment methodology, so prior year differences true up.
That percentage table and the exclusion for qualifying orphan drug sales are the big levers most teams watch. If your Medicaid supplemental rebates and 45C orphan information are not in the IRS data, your allocation can skew high. This is exactly why timely, complete Form 8947 submissions save you money and follow‑up work.
Step‑by‑Step Preparation Checklist
You do not need fancy software to get Form 8947 right. You do need clean inputs, a short review loop, and a tidy workpaper that matches what the IRS expects to see.
- Build your source list
- Pull a complete list of NDCs where your labeler code applies for the sales year.
- Tie quantities and brand names to official labeling records.
- Reconcile Medicaid state supplemental rebates
- Gather state confirmations and internal rebate ledgers.
- Agree totals and dates to your accounting method for the sales year.
- Document Section 45C orphan drug facts
- Identify each drug with a 45C credit allowed and the latest year claimed.
- Retain FDA and tax workpapers that support the orphan status for the period.
- Confirm controlled group and designated entity
- List members as of December 31 of the sales year.
- Confirm the designated entity name and EIN that will be used for payment and IRS correspondence. Joint and several liability applies, so treat this as a control point.
- Complete Form 8947 and send by the deadline
- Use the current form revision posted on IRS.gov.
- Mail to the Ogden address in the Internal Revenue Manual, and keep evidence of timely filing.
Aim to finish your 8947 package in October. That gives you breathing room for second‑set eyes and signature routing before the November 1 deadline.
Internal controls that help
- A single owner for the NDC list, a second reviewer for rebates and orphan data, and a final sign‑off by the tax lead or controller.
- A short reconciliation that proves your 8947 totals tie to your ledger and supporting statements.
- A shared folder with the mailed form, tracking receipt, and all backup.
Can you submit and then dispute later?
Yes. Even if you submit a clean 8947, agency data can still require a dispute. Use the error report process at the Ogden address the IRS publishes for the BPD program. Changes made through disputes flow into the final fee calculation.
Where an embedded team actually helps
If your accounting or tax team is buried during Q3 and Q4, outsourcing some of the prep work can be the difference between a calm filing and a scramble. At Accountably, we plug an experienced, U.S.‑led offshore team into your workflow to help with data gathering, NDC validation, rebate tie‑outs, and document packaging. You keep control, we do the repetitive lift inside your templates, and your reviewers see standardized workpapers. Use this when it meaningfully reduces review time and risk, not as a blanket replacement for your tax decisions.
Our north star is simple, help you submit accurate data on time, reduce dispute churn, and keep your in‑house team focused on judgment calls.
Disputes, Payments, and After‑Action Fixes
Dispute process in short
- Review the preliminary calculation for your entity.
- If you see a problem with program data or how your info was applied, submit an error report to the Ogden address shown in the IRM.
- Program agencies review program errors, the IRS considers other errors, and any accepted changes roll into the final fee.
Final letter and payment
Expect the final fee letter no later than August 31. Pay by September 30 via EFT. If you are part of a controlled group, pay using the designated entity’s EIN. All members are jointly and severally liable. The fee is not deductible under section 275.
Need a refund or adjustment after payment?
Use Form 843 for claims that relate to the branded prescription drug fee and include the Form 8947 that supported the IRS calculation. The IRS notes that interest related to this fee cannot be abated. Keep your correspondence and calculations handy for quick responses.
What Not To Include, and Why It Matters
- Do not include state‑only pharmaceutical program rebates in the Medicaid section. CMS has confirmed those programs are not part of the Medicaid Drug Rebate Program, so they are excluded from the fee base and should not be on Form 8947 or in error reports.
- Do not send incomplete forms. Filing is mandatory for covered entities above the threshold, and your statement is signed under penalties of perjury, and the IRS expects complete data.
Recordkeeping and Evidence
Keep books and records as long as they may be material to administration of the fee. In practice, preserve your NDC listings, rebate support, orphan drug documentation, 8947 workpapers, mailing proof, and any dispute correspondence for examination. The agencies provide the sales data, the IRS compiles and calculates, and your job is to be able to show how your inputs reduce the sales base.
A tidy file now shortens future dispute cycles. Think of your folder like an audit kit you can hand to a new reviewer in five minutes.
Common Confusions and Clean Answers
Is Form 8947 the same as Form 8949 or related to 1099‑B corrections?
No. Form 8949 is for reporting capital asset sales and reconciles with Forms 1099‑B or 1099‑S. Form 8947 is a branded prescription drug fee information form under ACA section 9008 and has nothing to do with broker basis or wash sales.
Is filing Form 8947 mandatory?
Yes, for covered entities above the threshold. A manufacturer or importer with gross receipts from branded prescription drug sales to a specified government program exceeding $5,000,000 in the data year must file. It is also the official channel to provide NDCs, Medicaid supplemental rebates, orphan drug information, and controlled group details that can reduce your fee allocation.
What is the deadline to file Form 8947?
File by November 1 of the calendar year before the fee year, or the next business day if November 1 is a weekend or legal holiday in the District of Columbia. For the 2025 fee year, the deadline was November 1, 2024.
When will we see the final fee letter and when is payment due?
The final fee calculation letter arrives no later than August 31 of the fee year. Payment is due by September 30 and must be made by electronic funds transfer.
Can we e‑file Form 8947?
The program guidance points you to mail the form to the Ogden address in the IRM. Keep evidence of timely filing and a complete digital copy of what you sent.
How do Section 45C orphan drug credits affect the fee?
Sales of branded prescription drugs for which a Section 45C orphan drug credit was allowed are excluded from the fee base, but only while the drug stays FDA-approved solely for the rare disease or condition; a later non-orphan approval can end the exclusion. List those drugs and the latest year the credit was allowed on Form 8947 so the IRS can apply the exclusion.
What about Medicaid state supplemental rebates?
Those amounts reduce the sales base used in the allocation, but report only the state supplemental rebates here, since the standard Medicaid Drug Rebate Program rebates are already netted from the CMS data the IRS uses. Report them for the sales year on Form 8947 using your method of accounting, and keep proof from state programs to support your figures.
We are a controlled group. Who pays?
Controlled groups pay under the designated entity’s EIN reported on Form 8947, and all members are jointly and severally liable.
We paid the fee, then identified an adjustment. How do we claim a refund?
Use Form 843 for fee‑related refund claims and attach the Form 8947 that supported the IRS’s fee calculation, along with your supporting documents.
Common Mistakes We See Every Season
The branded prescription drug fee turns on data quality, and the same handful of slips show up every cycle. Each one either inflates the fee or invites a dispute you could have avoided.
Reusable Checklists
These checklists are copy-paste ready for your firm SOPs. Drop them into your branded prescription drug fee workpaper and check items off as the package comes together.
Form 8947 data packet (Parts I to IV)
- Pull a complete Part I NDC list under your labeler code for the sales year, formatted per the Form 8947 instructions.
- Confirm each NDC is an NDA or BLA branded product and exclude ANDA generics.
- Gather Part II Medicaid state supplemental rebate confirmations and tie them to your ledger and method of accounting.
- Document Part III Section 45C orphan drug facts, including the latest year the credit was allowed.
- List Part IV controlled-group members and confirm the designated entity name and EIN.
- Reconcile your totals to supporting statements before review.
November filing and submission
- Download the current Rev. September 2018 form from IRS.gov and open it in desktop Adobe Acrobat Reader.
- Complete Parts I through IV and review against the data packet.
- Have the appropriate person sign; the statement is made under penalties of perjury.
- Mail to the Ogden, Utah address published in the Internal Revenue Manual.
- Keep proof of mailing and a full digital copy of what was sent.
- Calendar the statutory November 1 due date, using the next business day when it falls on a weekend.
Fee-year response window
- Watch for the IRS preliminary fee calculation, issued around March of the fee year.
- Reconcile the preliminary figure against your Form 8947 inputs and program data.
- Submit any error report to the Ogden address by May 15 of the fee year.
- Confirm the final fee calculation letter, due no later than August 31.
- Schedule the EFT payment so it clears by September 30 (under the designated entity EIN for a controlled group).
- Retain all correspondence and calculations for examination.
Keep 8947 Season From Stalling
The branded prescription drug fee runs on a fixed industry pool. The aggregate applicable amount is set at $2,800,000,000 for fee year 2019 and each year thereafter (ACA section 9008 and 26 CFR Part 51), so every covered entity's share depends on how cleanly its sales, rebate, and orphan drug data land in the IRS calculation. The work that decides that share happens in a narrow Q3 and Q4 window, on top of close and year-end, when the same people are already stretched.
The fix is not heroics in late October. It is treating the Form 8947 package as a standing workpaper that is assembled, reconciled, and reviewed on a schedule, the same way you would handle any recurring compliance deliverable.
- Build the Part I NDC list under your labeler code early, formatted per the Form 8947 instructions, so it is not a last-week scramble.
- Tie Part II Medicaid state supplemental rebates to state confirmations and your ledger, and keep standard Drug Rebate Program rebates out.
- Document Part III Section 45C orphan drug facts, including the latest year the credit was allowed.
- Lock Part IV controlled-group members and the designated entity EIN before signature routing.
- Pre-stage the fee-year calendar: preliminary calculation around March, error reports by May 15, final letter by August 31, and EFT payment by September 30.
When the calendar tightens, a structured delivery team can carry the repetitive lift, NDC validation, rebate tie-outs, and orphan drug substantiation, inside your own templates and review layers. That is the model behind our tax execution support: documented workpapers and a multi-layer review so the data is right before the IRS runs the numbers.
FAQs
What is Form 8947 for?
Form 8947, Report of Branded Prescription Drug Information, is how a covered entity gives the IRS the data used to compute the annual branded prescription drug fee under section 9008 of the Affordable Care Act. It reports National Drug Codes, Medicaid state supplemental rebates, Section 45C orphan drug information, and controlled group and designated entity details.
Who has to file Form 8947?
Filing is mandatory for a covered entity, a manufacturer or importer of branded prescription drugs, with gross receipts from branded prescription drug sales to a specified government program exceeding $5,000,000 in the data year. Companies that sell only generics filed through the ANDA pathway, or that sell only to commercial markets, are not covered.
What is the deadline to file Form 8947?
File by November 1 of the calendar year before the fee year, or the next business day if November 1 falls on a weekend or legal holiday. November 1, 2025 fell on a weekend, so the deadline for the 2024 sales year shifted to November 3, 2025.
When does the final fee letter arrive and when is payment due?
The IRS issues a preliminary fee calculation, then sends the final fee calculation letter no later than August 31 of the fee year. Payment is due by September 30 of the fee year and must be made by electronic funds transfer. The fee is not deductible for federal income tax purposes.
How do Section 45C orphan drug credits affect the fee?
Sales of a branded prescription drug for which a Section 45C orphan drug credit was allowed are excluded from the fee base, but only while the drug stays FDA-approved solely for the rare disease or condition. A later non-orphan approval can end the exclusion, so a name on an orphan list is not enough; report each qualifying drug and the latest year the credit was allowed on Form 8947.
We are a controlled group. Who files and who pays?
All members of a controlled group are treated as a single covered entity, so members do not file separately. One designated entity files a single Form 8947, lists the members in Part IV, and handles all IRS correspondence and payment of the fee on the group's behalf.
What happens if a covered entity does not file?
The IRS will still calculate the fee using data from CMS, the Department of Veterans Affairs, and the Department of Defense. Without Form 8947, though, the entity loses the chance to subtract orphan drug sales and Medicaid state supplemental rebates, which usually raises the assessed fee.